MyoKardia hits life high after encouraging heart drug data

From Reuters - August 7, 2017

(Reuters) - Shares of MyoKardia Inc hit a record high on Monday after the company said its experimental drug for an inherited heart disease met the main goal in a small mid-stage study.

Data on 10 patients showed that the drug, mavacamten, induced a statistically significant improvement in blood flow and aerobic capacity in patients with obstructive hypertrophic cardiomyopathy - a common cause of sudden cardiac arrest in young people, including athletes.

The condition occurs when heart muscle cells enlarge and can thicken ventricles walls, usually the left ventricle, according to the American Heart Association.

"The study results are much better than what most investors had anticipated or expected," Wedbush Securities' analyst David Nierengarten told Reuters.

Data announced on Monday came from the first group of patients of the study. A second group will get a smaller dose of the drug, and that data is expected in early 2018, the company said. The drug is being developed in collaboration with France's Sanofi.


Continue reading at Reuters »